Clinical Trials List
2022-08-01 - 2026-08-31
Phase II
Recruiting7
ICD-10C67.9
Malignant neoplasm of bladder, unspecified
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9188.9
Malignant neoplasm of bladder, part unspecified
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- FU-JEN HSUEH Division of Hematology & Oncology
- Ying-Chun Shen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林昶廷 Division of Hematology & Oncology
- 陳彥豪 Division of Hematology & Oncology
- Tai-Jan Chiu Division of Hematology & Oncology
- 曾亮節 Division of Radiation Therapy
- Shau-Hsuan Li Division of Hematology & Oncology
- 陳彥仰 Division of Hematology & Oncology
- 劉建廷 Division of Hematology & Oncology
- 吳佳哲 Division of Hematology & Oncology
- 郭明濬 Division of Hematology & Oncology
- 黃詩喻 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Jia-An Hong Division of Radiology
- Jiun-I Lai Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Che-Hung Lin Division of Hematology & Oncology
- 鄭富銘 Division of Hematology & Oncology
- Chi-Ping Huang Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ching-Chia Li Division of Urology
- Jeng-Shiun Du Division of Hematology & Oncology
- Tsu-Ming Chien Division of Urology
- Hung-Lung Ke Division of Urology
- 阮雍順 Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
45 participants
-
Global
252 participants
